Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple well-established treatment options, many of which are generic. Tricyclic antidepressants (TCAs), antiepileptic drugs, and opioid-based drugs are most commonly used to treat PDN patients. However, current analgesics offer only inadequate pain relief, and so it is important to understand use of current therapies in newly diagnosed and recently treated PDN patients thought the use of national patient-level claims data.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States
Real World data: Longitudinal patient-level claims data analysis
Key companies: Pfizer, Eli Lilly, Janssen Pharmaceuticals, Depomed
Key drugs: Lyrica, gabapentin (Neurontin, generics), duloxetine (Cymbalta, generics), Nucynta ER
Key Analysis provided: